Siltuximab
IL-6 | |
---|---|
Clinical data | |
Trade names | Sylvant |
Other names | CNTO 328 |
License data | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6450H9932N1688O2016S50 |
Molar mass | 144983.21 g·mol−1 |
(what is this?) (verify) |
Siltuximab (
On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant
Medical uses
Used for the treatment of idiopathic multicentric Castleman disease (iMCD).[13]
Clinical trials
Siltuximab has demonstrated significant efficacy and safety in patients with idiopathic multicentric
Side effects
Siltuximab may lower resistance to infections and should not be administered to patients with severe infections. Siltuximab should be discontinued in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions or cytokine release syndromes. Live vaccines should not be administered to patients receiving siltuximab since IL-6 inhibition may interfere with normal immune response to new antigens.[13]
Common The following has been shown to occur in treatment of Multicentric
- Peripheral edema
- Abdominal Pain
- Pruritus
- Increased weight
- Rash
- Hyperuricemia
- Upper respiratory tract infections
Long term exposure
- Upper respiratory tract infection
- Pain in extremities
- Arthralgia
- Fatigue
Drug interactions
Siltuximab may increase
Mechanism of action
Siltuximab is a chimeric
References
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ "Siltuximab mechanism of action". HemOnc.org - A Free Hematology/Oncology Reference.
- PMID 26854213.
- PMID 20808314.
- S2CID 32034042.
- ^ "Siltuximab". ClinicalTrials.gov.
- PMID 20625121.
- S2CID 29140516.
- ^ "Sylvant official website".
- ^ "Siltuximab approval". Food and Drug Administration. 23 April 2014. Archived from the original on 3 June 2014.
- ^ "Castleman disease: Siltuximab cancer regimen & references". HemOnc.org - A Free Hematology/Oncology Reference.
- ^ a b c d e "Sylvant Prescribing Information" (PDF). janssenmd. Retrieved 3 November 2014.
- PMID 26634298.
- PMID 27904739.
- S2CID 40363229.
- S2CID 30691176.
- PMID 27363832.